Triplet therapyIn the new study, published in Cancer Discovery,...

Triplet therapy

In the new study, published in Cancer Discovery, researchers combined palbociclib, a CDK4/6 inhibitor, with PI3K inhibitor taselisib and hormone therapy fulvestrant. The results demonstrate an important proof of concept for a new treatment combination and could lead to the CDK4/6-PI3K inhibitor combination being used to treat advanced breast cancer in the future.

https://medicalxpress.com/news/2021-03-three-drug-combination-advanced-breast-cancer.html